Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellSource CoTSE:4880 -5.34%70 Operating Margin % is 7.08% as of Apr. 2026, which is 71% below its 10-year median of 24.33. GuruFocus rates TSE:4880 with a GF Score™ of 70/100 and a GF Value™ of 円777.56 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 942 Biotechnology companies, CellSource Co ranks better than 77.18% on this metric.
CellSource Co (TSE:4880) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
CellSource Co Operating Margin % Related Terms
CellSource Co Operating Margin % Historical Data
* Premium members only.
The historical data trend for CellSource Co's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4880 vs VRTX, REGN, RVMD: Operating Margin % Comparison
For the Biotechnology subindustry, CellSource Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's Operating Margin % distribution charts can be found below:
* The bar in red indicates where CellSource Co's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
CellSource Co's Operating Margin % for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellSource Co (TSE:4880) has a Operating Margin % of 7.08% as of Apr. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on CellSource Co and its competitors. This is 71% below median its historical median of 24.33. Over the past decade, CellSource Co's Operating Margin % has ranged from 2.97 to 36.76. According to the industry distribution chart, CellSource Co ranks #215 out of 942 companies in the Biotechnology industry, placing it in the top 22.8%.
Is CellSource Co's Operating Margin % too high?
CellSource Co's current Operating Margin % of 7.08% is 71% below median its 10-year median of 24.33. Over the past 10 years, this metric has ranged from a low of 2.97 to a high of 36.76. Based on the distribution chart, CellSource Co ranks #215 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CellSource Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #215 out of 942 companies for Operating Margin %. This places CellSource Co in the top 23% of its industry — outperforming the majority of peers. Historically, CellSource Co's own Operating Margin % has ranged from 2.97 to 36.76 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on CellSource Co and its competitors. CellSource Co's current Operating Margin % is 7.08%, which is 71% below median its own 10-year median of 24.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円777.56, compared to a current price of 円337.00 — trading 56.7% below its estimated fair value. The current Operating Margin % is 7.08%, which is 71% below median its 10-year median of 24.33. CellSource Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current Operating Margin % is 7.08% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円337.00 is trading 56.7% below its estimated GF Value™ of 円777.56.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
Operating Margin %: 7.08% (71% below median its 10-year median of 24.33)
GF Value™: 円777.56 vs. price of 円337.00 (56.7% below fair value)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
70GF Score
Get the complete analysis for TSE:4880
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
